Last reviewed · How we verify
Chloroquine, Tafenoquine
At a glance
| Generic name | Chloroquine, Tafenoquine |
|---|---|
| Also known as | Tafenoquine, Chloroquine |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Pruritus
- Dizziness
- Myalgia
- Nausea
- Vomiting
- Abdominal pain upper
- Nasopharyngitis
- Diarrhoea
- Pharyngitis
- Urinary tract infection
- Back pain
Key clinical trials
- This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria (PHASE2)
- Vivax Elimination With Tafenoquine (VET) Study (PHASE4)
- FocaL Mass Drug Administration for Vivax Malaria Elimination (PHASE3)
- An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older (PHASE3)
- Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield (NA)
- ACT vs CQ With Tafenoquine for P. Vivax Mono-infection (PHASE4)
- Southeast Asia Dose Optimization of Tafenoquine (PHASE4)
- Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chloroquine, Tafenoquine CI brief — competitive landscape report
- Chloroquine, Tafenoquine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI